Full Professor(heuristic)

Lung Cancer Treatments and Mutations · Pulmonary and Respiratory Medicine

Compare more Pulmonary and Respiratory Medicine professors.

h-index131
i10-index554
Publications2,459
Citations69,104

Grants

9 total · 1 active

NIH #R01CA287279

Deciphering the structural determinants of response and resistance to HER2-targeted antibody-drug conjugates and tyrosine kinase inhibitors for HER2-mutant Non-Small Cell Lung Cancer

Active
Amount
$600K–$700K
Period
2025-04-01 → 2030-03-31
PIs
2

Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR

NIH #P30CA016672

10 Lung Cancer

Amount
<$100K
Period
1996-08-28 → 2026-06-30
PIs
1

Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR

NIH #U01CA256780

Molecular and immunological heterogeneity of Small Cell Lung Cancer (SCLC) and its impact on relapse and therapeutic response

Amount
$600K–$700K
Period
2021-06-01 → 2026-05-31
PIs
3

Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR

Active grants are a starting point, not proof of an opening. Confirm recruiting and funding with the professor, current students, and your written offer. Learn how to verify PhD funding →

All Grants

9 total · 1 active

NIH #R01CA287279

Deciphering the structural determinants of response and resistance to HER2-targeted antibody-drug conjugates and tyrosine kinase inhibitors for HER2-mutant Non-Small Cell Lung Cancer

Active
Amount
$600K–$700K
Period
2025-04-01 → 2030-03-31
PIs
2

Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR

NIH #P30CA016672

10 Lung Cancer

Amount
<$100K
Period
1996-08-28 → 2026-06-30
PIs
1

Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR

NIH #U01CA256780

Molecular and immunological heterogeneity of Small Cell Lung Cancer (SCLC) and its impact on relapse and therapeutic response

Amount
$600K–$700K
Period
2021-06-01 → 2026-05-31
PIs
3

Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR

NIH #P50CA070907

Targeting Lung Cancer Vulnerabilities

Amount
$2M–$3M
Period
1997-09-05 → 2025-08-31
PIs
3

Awarded at UT SOUTHWESTERN MEDICAL CENTER

NIH #R01CA247975

Molecular features impacting drug resistance in atypical EGFR exon 18 and exon 20 mutant non-small cell lung cancers and the development of novel mutant-selective inhibitors

Amount
$500K–$600K
Period
2020-04-01 → 2025-03-31
PIs
2

Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR

NIH #R01CA234183

Therapeutic strategies against EGFR exon 20 mutant lung cancer

Amount
$500K–$600K
Period
2019-12-01 → 2024-11-30
PIs
2

Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR

NIH #U01CA213273

Novel therapeutic approaches for enhancing anti-tumor immunity in SCLC

Amount
$700K–$800K
Period
2017-08-01 → 2022-07-31
PIs
3

Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR

NIH #R01CA205150

Therapeutic approaches for LKB1-deficient non-small cell lung cancer

Amount
$600K–$700K
Period
2016-04-01 → 2021-03-31
PIs
2

Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR

NIH #R01CA190628

Overcoming Resistance to Anti-EGFR Therapy by Drug Repurposing

Amount
$500K–$600K
Period
2015-08-01 → 2020-07-31
PIs
2

Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR

Recent Public Signals

  1. New paper: Unbiased avidity-based isolation of antigen-specific T cells (Journal for ImmunoTherapy of Cancer)2026-07-01
  2. New NIH award: Deciphering the structural determinants of response and resistance to HER2-targeted antibody-drug conjugates and tyrosine kinase inhibitors for HER2-mutant Non-Small Cell Lung Cancer2025-04-01

Are you this professor?

No account needed — verify once with your ORCID iD to set recruiting status and correct your rank.

Data Freshness

  • Publications as of 2026-07-09
  • Grants as of 2026-09-03

Data may not be current

Find elsewhere

Institution / lab homepage Search on ResearchGate

ORCID: 0000-0001-9068-8942

Professor Insights

Career Trajectory